Should atezolizumab be used with chemotherapy in the first line treatment of ES-SCLC?
Has the publication of IMpower133 changed standard of care?
Answer from: Medical Oncologist at Academic Institution
Yes, as noted by the presenter of the results of IMpower 133 at WCLC, atezolizumab+ etoposide/carboplatin is a new standard of care for front-line therapy of ES-SCLC. This result should be embraced as it represents the first meaningful advance in the initial treatment of SCLC in...
Sign in or Register to read more